Get the Stockscreener App
69.78
2.39%
1.63
After Hours:
69.78
Boston Scientific Corp stock is traded at $69.78, with a volume of 9.43M.
It is up +2.39% in the last 24 hours and down -5.04% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$68.15
Open:
$69
24h Volume:
9.43M
Relative Volume:
0.67
Market Cap:
$103.71B
Revenue:
$20.08B
Net Income/Loss:
$2.89B
P/E Ratio:
35.99
EPS:
1.9391
Net Cash Flow:
$3.66B
1W Performance:
-2.10%
1M Performance:
-5.04%
6M Performance:
-28.90%
1Y Performance:
-32.31%
1-Day Range:
$68.60
$70.10
1-Week Range:
$68.03
$71.78
52-Week Range:
$67.56
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.62 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade) - Seeking Alpha
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Boston Scientific Corporation (BSX) A Good Stock To Buy Now? - Insider Monkey
Boston Scientific Corp. stock shows resilient fundamentals amid volatile medtech market pressures - AD HOC NEWS
Why Boston Scientific's Big Dip Could Be a Bigger Opportunity - TradingView
BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - GlobeNewswire Inc.
Deadline Alert: Boston Scientific Corporation (BSX) - GlobeNewswire
A Quick Look at Today's Ratings for Boston Scientific(BSX.US), With a Forecast Between $90 to $120 - 富途牛牛
BSX Shareholder Alert: Boston Scientific Corporation Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - Barchart.com
Evercore ISI reiterates Boston Scientific stock rating on growth outlook - Investing.com UK
Evercore ISI reiterates Boston Scientific stock rating on growth outlook By Investing.com - Investing.com India
Stifel reiterates Boston Scientific stock rating ahead of trial data - Investing.com
Boston Scientific (BSX) Joins Evercore's Tactical Outperform Lis - GuruFocus
Boston Scientific Corporation $BSX Shares Sold by Park Avenue Securities LLC - MarketBeat
Avanza Fonder AB Acquires 21,210 Shares of Boston Scientific Corporation $BSX - MarketBeat
Robbins LLP Urges BSX Stockholders Who Lost Money Investing in Boston Scientific Corporation to Contact the Firm for Information About Leading the Class Action - Barchart.com
BSX Stock Quote Price and Forecast - CNN
ROSEN, A RANKED AND LEADING FIRM, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
BSX INVESTOR ALERT: Boston Scientific Corporation Investors - GlobeNewswire
Boston Scientific (NYSE:BSX) Falls as Recall Draws S&P 500 Focus - Kalkine Media
Tounjian Advisory Partners LLC Makes New Investment in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific’s EMEA Urology Push May Reframe Valuation Story - simplywall.st
Is Boston Scientific (BSX) Still Attractive After Its Recent Share Price Pullback? - Yahoo Finance
BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - TMX Newsfile
Truist Cuts PT on Boston Scientific Corporation (BSX) to $92 From $95 – Here’s Why - Insider Monkey
Jim Cramer on Boston Scientific: “This Stock Was One of the Greatest Performers, It’s Not Anymore” - Insider Monkey
Needham & Company LLC Reiterates "Buy" Rating for Boston Scientific (NYSE:BSX) - MarketBeat
BOSTON SCIENTIFIC CORP ($BSX) CEO 2025 Pay Revealed - Quiver Quantitative
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
ROSEN, SKILLED TRIAL COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Boston Scientific (BSX) Faces Scrutiny Over Pacemaker Battery Re - GuruFocus
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Boston Scientific Corporation (BSX) - TMX Newsfile
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming DeadlinesBSX - ChartMill
BSX DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Portnoy Law Firm Announces Class Action on Behalf of Boston Scientific Corporation Investors - GlobeNewswire Inc.
Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress? - MSN
INVESTOR ALERT: Boston Scientific Corporation Investors - GlobeNewswire
Boston Scientific Faces Investor Lawsuit Alleging Misleading Statements About Electrophysiology Growth - TipRanks
Boston Scientific (BSX) Rating Maintained, Price Target Lowered by Truist Securities | BSX Stock News - GuruFocus
Truist Financial Issues Pessimistic Forecast for Boston Scientific (NYSE:BSX) Stock Price - MarketBeat
Truist cuts Boston Scientific stock price target on valuation - Investing.com
Truist Cuts Price Target on Boston Scientific to $92 From $95, Keeps Buy Rating - marketscreener.com
Danske Bank A S Invests $94.51 Million in Boston Scientific Corporation $BSX - MarketBeat
Stance Capital LLC Grows Stock Holdings in Boston Scientific Corporation $BSX - MarketBeat
CIBC Bancorp USA Inc. Makes New $59 Million Investment in Boston Scientific Corporation $BSX - MarketBeat
Avity Investment Management Inc. Takes Position in Boston Scientific Corporation $BSX - MarketBeat
Danica Pension Livsforsikringsaktieselskab Acquires New Position in Boston Scientific Corporation $BSX - MarketBeat
BSX Technical Analysis | Trend, Signals & Chart Patterns | BOSTON SCIENTIFIC CORP (NYSE:BSX) - ChartMill
Boston Scientific (NYSE: BSX) plans 2026 virtual meeting with major governance votes - Stock Titan
Why Boston Scientific (BSX) Outpaced the Stock Market Today - Yahoo Finance
Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - GuruFocus
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):